Angiolymphoid hyperplasia with eosinophilia (ALHE) is a benign angioproliferative disorder with an uncertain pathogenesis.1 The treatment of ALHE includes surgical excision, destructive therapies, and medical therapies, many of which are often ineffective.2 In this article, we describe the clinical response to medications targeting eosinophilic inflammation in the treatment of ALHE, including the novel use of dupilumab, which was associated with complete resolution.
Franke K, Notaro E, Moshiri AS, Ayars A, Kalus A. Use of Dupilumab and Eosinophil Targeted Therapy in Treating Angiolymphoid Hyperplasia With Eosinophilia. JAMA Dermatol. 2022;158(8):960–962. doi:10.1001/jamadermatol.2022.1969
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.